The co-lead investigator for a metastatic breast cancer trial combining Theraclion‘s focused ultrasound technology and immunotherapy discussed the design and rationale of the study, the France-based company reported today. Dr. David Brenin, chief of breast surgery at the University of Virginia School of Medicine, said that although immuno-oncology has been gaining steam as a way to […]
Featured
Intersect ENT touts meta-analysis of steroid-releasing sinus implant
Intersect ENT (NSDQ:XENT) touted data today from a meta-analysis of two studies assessing the safety and efficacy of its investigational steroid-releasing sinus implant, Sinuva. The studies evaluated Sinuva in patients with recurrent and medically refractory nasal polyps. The meta-analysis, which was presented at the American Rhinologic Society’s annual meeting, included data from the Resolve and Resolve […]
Allergan alleges Imprimis makes, sells and promotes unapproved drugs – and Imprimis fires back
Last week, Allergan (NYSE:AGN) said that it filed lawsuits against Imprimis Pharmaceuticals (NSDQ:IMMY), Prescriber’s Choice and Sincerus Florida, claiming that the companies manufacture, sell and promote unapproved new drugs. The pharmaceutical giant filed suit in the U.S. District Court for the Central District of California. Today, Imprimis fired back at Allergan, denying the allegations and saying that […]
Regeneron, Sanofi tout topline Ph3 data for injectable asthma drug
Sanofi (NYSE:SNY) and Regeneron (NSDQ:REGN) touted data today from the pivotal Phase III trial of dupilumab in a group of patients with uncontrolled, persistent asthma. The drug is already approved for adults with certain forms of eczema. The two companies said they plan to seek FDA approval of dupilumab in asthma by the end of the year. […]
Medtronic recalls insulin infusion sets
Medtronic (NYSE:MDT) said today that it’s recalling some of the infusion sets used with its insulin pumps due to problems with a discontinued component. The Fridley, Minn.-based medical device titan said the problem involves a vent membrane that’s susceptible to blockage during priming and fill-tubing. No pumps or glucose sensors are affected by the recall, Medtronic […]
Medtech stories we missed this week: September 8, 2017
From BrainScope’s pediatric traumatic brain injury assessment device to EOS Imaging releasing new surgery planning software, here are seven medtech stories we missed this week but thought were still worth a mention. 1. BrainScope to develop pediatric traumatic brain injury assessment device BrainScope announced in a Sept. 7 press release that it will immediately start creating […]
Replicel prototypes its next-gen dermal injector
RepliCel Life Sciences (OTC:REPCF) said yesterday that it has developed prototypes of its RCI-02 motorized injection device designed with programmable depth and volume, as well as interchangeable needle head configurations. The injector was built to deliver an array of substances, including dermal fillers, drugs, cells or biologics intradermally, subcutaneously or intramuscularly. The company said it hopes […]
DarioHealth launches CGM mobile app for certain Android devices
Digital health company DarioHealth (NSDQ:DRIO) this week launched its Dario app in Google Play’s U.S. app store, making it available for certain Android devices. The mobile app accompanies DarioHealth’s blood glucose monitoring system, which connects via a headphone jack to turn a mobile device into a glucose monitor, according to the company. “We are very excited to […]
Tandem Diabetes Care shareholders approve reverse split
Tandem Diabetes Care (NSDQ:TNDM) shareholders met yesterday and approved a proposal to effect a reverse stock split at a ratio between 1-for-8 and 1-for-12, according to a regulatory document. In a statement filed with the SEC in July, the San Diego, Calif.-based company told shareholders that it believed a reverse stock split would help Tandem keep […]
Lyndra lands $105m deal with Allergan for once-weekly Alzheimer’s drugs
Boston-based startup Lyndra said today that it is partnering with pharma giant Allergan (NYSE:AGN) to develop orally administered, once-weekly products for the treatment of Alzheimer’s disease. The collaboration will combine Allergan’s proprietary Alzheimer’s drugs with Lyndra’s sustained-release technology, which is designed to temporarily reside in the stomach for up to one week while delivering a drug. […]